ArticleRSC advances2022
Engineering of appropriate pore size combined with sulfonic functionalization in a Zr-MOF with reo topology for the ultra-high removal of cationic malachite green dye from an aqueous medium.
Article in RSC advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mesoporous zirconium based metal-organic frameworks, a topological review.RSC advances · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A Zr-based metal-organic framework with reo topology, denoted as Reo-MOF-1, was fabricated through a solvothermal method capable of efficiently removing the cationic MG dye from an aqueous medium. The effect of pH solution, adsorbent content, adsorption isotherm, and kinetics on the MG capture was observed to determine the optimal conditions. Accordingly, the maximum adsorption capacity of MG over H
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.